Search hospitals > Oregon > Portland
Summit Research Network
Claim this profilePortland, Oregon 97210
Global Leader in Alzheimer's Disease
Global Leader in Depression
Conducts research for Major Depressive Disorder
Conducts research for Migraine
Conducts research for Attention Deficit Hyperactivity Disorder (ADHD)
136 reported clinical trials
3 medical researchers
Summary
Summit Research Network is a medical facility located in Portland, Oregon. This center is recognized for care of Alzheimer's Disease, Depression, Major Depressive Disorder, Migraine, Attention Deficit Hyperactivity Disorder (ADHD) and other specialties. Summit Research Network is involved with conducting 136 clinical trials across 57 conditions. There are 3 research doctors associated with this hospital, such as Scott Losk, James H. Bergthold, and MaryAnn Conrad.Area of expertise
1Alzheimer's Disease
Global LeaderAβ1-42 positive
APOE4 positive
APOE4 negative
2Depression
Global LeaderTop PIs
Scott LoskSummit Research Network3 years of reported clinical research
Studies Alzheimer's Disease
Studies Dementia
8 reported clinical trials
8 drugs studied
James H. BergtholdSummit Headlands3 years of reported clinical research
Studies Obesity
Studies Diabetes
3 reported clinical trials
3 drugs studied
MaryAnn ConradSummit Headlands1 year of reported clinical research
Studies Diabetes
Studies Obesity
1 reported clinical trial
2 drugs studied
Clinical Trials running at Summit Research Network
Alzheimer's Disease
Thrombotic Microangiopathy
Vascular Disease
Dermatomyositis
AL002
for Alzheimer's Disease
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Recruiting1 award Phase 2
Oral ABBV-552
for Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating symptoms of early AD. Adverse events, change in disease activity, how ABBV-552 moves through body of participants and the body response to ABBV-552 will be assessed. ABBV-552 is an investigational drug being developed for the treatment of Alzheimer's disease (AD). Study doctors put the participants in 1 of 4 groups (3 active dose groups and a placebo group), called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Approximately 240 participants aged 50-90 years with mild AD will be enrolled in approximately 60 sites across the world. Participants will receive oral ABBV-552 or placebo capsules once daily for 12 weeks and followed for 30 days after the last dose of study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting0 awards Phase 2
ACU193
for Early Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Recruiting0 awards Phase 2 & 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Summit Research Network?
Summit Research Network is a medical facility located in Portland, Oregon. This center is recognized for care of Alzheimer's Disease, Depression, Major Depressive Disorder, Migraine, Attention Deficit Hyperactivity Disorder (ADHD) and other specialties. Summit Research Network is involved with conducting 136 clinical trials across 57 conditions. There are 3 research doctors associated with this hospital, such as Scott Losk, James H. Bergthold, and MaryAnn Conrad.